Page 190 - 80 guidelines for the treatment of malaria_opt

nd
Guidelines for the treatment of malaria – 2 edition

importance CRITICAL CRITICAL IMPORTANT IMPORTANT IMPORTANT IMPORTANT

Quality MODERATE MODERATE LOW
– – –
Is one ACT (plus primaquine) more effective than another at treating P. vivax in areas with CQ resistant P. vivax?
473 fewer per 1000 (from 349 fewer 242 fewer per 1000 (from 144 fewer

Absolute – to 524 fewer) to 254 fewer) Not estimable – –

effect Relative risk (95% CI) – RR 0.16 (0.07–0.38) RR 0.06 (0.01–0.44) Not estimable – –

summary of findings no. of patients AL DHA + PPQ – 40/71 5/55 (56.3%) (9.1%) 19/74 1/65 (25.7%) (1.5%) 0/85 0/90 (0%) (0%) – –

considerations – – –

Other – None None None –

Imprecision – No serious imprecision 5 No serious imprecision 5 Serious imprecision 6 – –

Indirectness – Serious 4 Serious 4 Serious 4 – –

Inconsistency Not applicable Not applicable Not applicable

Limitations EFFICACy: recurrence of P . vivax parasitaemia – by day 63 - not reported 1 – No serious limitations 3 No serious limitations 3 No serious limitations 3 – –

GRADE Table A9.6.2 Quality assessment Design – – EFFICACy: recurrence of P . vivax parasitaemia – by day 42 Randomized trial 2 EFFICACy: recurrence of P . vivax parasitaemia – by day 28 Randomized trial 2 EFFICACy: failure to initially clear P. vivax – days 0–3 Randomized trial 2 PUBLIC HEALTH BENEFIT: anaemia 7 – – HARMS: serio

176 No. of studies 0 1 1 1 0 0